Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Stamos Capital gave its Amgen investment a hearty boost, snatching up 2,760 more shares in Q4—a 69.5% increase. Stamos Capital Partners L.P.'s holdings in Amgen were worth $1,754,000 as of its most ...

In the latest trading session, Amgen (AMGN) closed at $277.29, marking a -1.89% move from the previous day. This change lagged the S&P 500's 0.13% gain on the day. At the same time, the Dow lost 1.33% ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

Advisors Capital Management upped its Amgen stake by 6.2% in Q4, scooping up an extra 3,427 shares valued at $15.3 million. Amgen’s fourth-quarter earnings beat expectations with a $5.31 per share ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...